Dr. Ritesh Patil
Research ScientistState University of New York, USA
Highest Degree
M.D. in Hematology Oncology from State University of New York, USA
Share this Profile
State University of New York, USA
Biography
Dr. Ritesh Patil is currently working as Hematology/Oncology Fellow at State University of New York, USA. He obtained his M.D. in Hematology Oncology from same University. His main area of interest related to Biomedical Sciences, and Medicine. His area of expertise includes Hematology, Oncology, Internal Medicine, Cancer, Blood, Chemotherapy, Case Report, Review Articles, Original Research, Breast Cancer, Vaccine, Cancer Prevention, Epidemiology, Statistics, Disease, Leukemia, Lymphoma, Anemia, Thrombocytopenia, Pompe Disease, Leucopenia, Malignancy, and Infection. He has published 11 research papers in peer review journals, 20 abstracts in peer review journals contributed as author/co-author.
Area of Interest:
Biomedical Sciences
100%
Cancer
62%
Hematology
90%
Leukemia
75%
Oncology
55%
Research Publications in Numbers
Books
0
0
Chapters
0
0
Articles
0
0
Abstracts
0
0
Selected Publications
- Mittendorf, E.A., G.T. Clifton, J.P. Holmes, K.S. Clive and R. Patil et al., 2012. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US military cancer institute clinical trials group study I-01 and I-02. Cancer, 118: 2594-2602.
CrossRef | PubMed | Direct Link | - Patil, R., T. Patil, L. Schenfeld and S. Massoud, 2011. Mycobacterium porcinum peritonitis in a patient on continuous ambulatory peritoneal dialysis. J. Gen. Internal Med., 26: 346-348.
CrossRef | PubMed | Direct Link | - Patil, R., T. Patil and K.M.A. Hussain, 2011. Staphylococcus lugdunensis native tricuspid valve endocarditis: a case report and review of literature. J. Gen. Internal Med., 26: 1209-1211.
CrossRef | PubMed | Direct Link | - Holmes, J.P., G.T. Clifton, R. Patil, L.C. Benavides and J.D. Gates et al., 2011. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: From US military cancer institute clinical trials group study I-01 and I-02. Cancer, 117: 463-471.
CrossRef | PubMed | Direct Link | - Patil, R., G.T. Clifton, J.P. Holmes, A. Amin and M.G. Carmichael et al., 2010. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J. Am. Coll. Surgeons, 210: 140-147.
CrossRef | PubMed | Direct Link | - Patil, R. and J.L. DePriest, 2009. Visual hallucinations in a patient with adult onset acid maltase deficiency disorder. J. Gen. Internal Med., 24: 683-686.
CrossRef | PubMed | Direct Link | - Benavides, L.C., J.D. Gates, M.G. Carmichael, R. Patel and J.P. Holmes et al., 2009. The impact of HER2/neu expression level on response to the E75 vaccine: from u.s. military cancer institute clinical trials group study I-01 and I-02. Clin. Cancer Res., 15: 2895-2904.
CrossRef | PubMed | Direct Link | - Holmes, J.P., J.D. Gates, L.C. Benavides, M.T. Hueman and M.G. Carmichael et al., 2008. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: From US military cancer institute clinical trials group study I-01 and I-02. Cancer, 113: 1666-1675.
CrossRef | PubMed | Direct Link |